Second-site suppressor mutations reveal connection between the drug-binding pocket and nucleotide-binding domain 1 of human P-glycoprotein (ABCB1)

被引:5
|
作者
Murakami, Megumi [1 ]
Sajid, Andaleeb [1 ]
Lusvarghi, Sabrina [1 ]
Durell, Stewart R. [1 ]
Abel, Biebele [1 ]
Vahedi, Shahrooz [1 ]
Golin, John [2 ]
Ambudkar, Suresh V. [3 ]
机构
[1] NCI, NIH, Ctr Canc Res, Lab Cell Biol, Bethesda, MD 20892 USA
[2] Catholic Univ Amer, Dept Biol, Washington, DC 20064 USA
[3] NCI, Cell Biol Lab, Ctr Canc Res, NIH, 37 Convent Dr,Room 2120, Bethesda, MD 20892 USA
基金
美国国家卫生研究院; 日本学术振兴会;
关键词
ABC transporter; Multidrug resistance; P-glycoprotein; Second -site suppressors; Molecular dynamics simulations; MULTIDRUG-RESISTANCE; ATP HYDROLYSIS; CATALYTIC CYCLE; TRANSPORT; EXPRESSION; INHIBITION; SUBSTRATE; TRANSLOCATION; MODULATION; INTERFACE;
D O I
10.1016/j.drup.2023.101009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Human P-glycoprotein (P-gp) or ABCB1 is overexpressed in many cancers and has been implicated in altering the bioavailability of chemotherapeutic drugs due to their efflux, resulting in the development of chemoresistance. To elucidate the mechanistic aspects and structure-function relationships of P-gp, we previously utilized a tyrosine (Y)-enriched P-gp mutant (15Y) and demonstrated that at least 15 conserved residues in the drug -binding pocket of P-gp are responsible for optimal substrate interaction and transport. To further understand the role of these 15 residues, two new mutants were generated, namely 6Y with the substitution of six residues (F72, F303, I306, F314, F336 and L339) with Y in transmembrane domain (TMD) 1 and 9Y with nine sub-stitutions (F732, F759, F770, F938, F942, M949, L975, F983 and F994) in TMD2. Although both the mutants were expressed at normal levels at the cell surface, the 6Y mutant failed to transport all the tested substrates except Bodipy-verapamil, whereas the 9Y mutant effluxed all tested substrates in a manner very similar to that of the wild-type protein. Further mutational analysis revealed that two second-site mutations, one in intracellular helix (ICH) 4 (F916Y) and one in the Q loop of nucleotide-binding domain (NBD) 1 (F480Y) restored the transport function of 6Y. Additional biochemical data and comparative molecular dynamics simulations of the 6Y and 6Y+F916Y mutant indicate that the Q-loop of NBD1 of P-gp communicates with the substrate-binding sites in the transmembrane region through ICH4.This is the first evidence for the existence of second-site suppressors in human P-gp that allow recovery of the loss of transport function caused by primary mutations. Further study of such mutations could facilitate mapping of the communication pathway between the substrate-binding pocket and the NBDs of P-gp and possibly other ABC drug transporters.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Mutations in either nucleotide-binding site of P-glycoprotein (Mdr3) prevent vanadate trapping of nucleotide at both sites
    Urbatsch, IL
    Beaudet, L
    Carrier, I
    Gros, P
    BIOCHEMISTRY, 1998, 37 (13) : 4592 - 4602
  • [22] The "LSGGQ" motif in each nucleotide-binding domain of human P-glycoprotein is adjacent to the opposing Walker A sequence
    Loo, TW
    Bartlett, MC
    Clarke, DM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (44) : 41303 - 41306
  • [23] Identification of residues in the drug-binding site of human P-glycoprotein using a thiol-reactive substrate
    Loo, TW
    Clarke, DM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (51) : 31945 - 31948
  • [24] Suppressor mutations in the transmembrane segments of P-glycoprotein promote maturation of processing mutants and disrupt a subset of drug-binding sites
    Loo, Tip W.
    Bartlett, M. Claire
    Clarke, David M.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (44) : 32043 - 32052
  • [25] Human-Mouse Chimeras with Normal Expression and Function Reveal That Major Domain Swapping Is Tolerated by P-Glycoprotein (ABCB1)
    Pluchino, Kristen M.
    Hall, Matthew D.
    Moen, Janna K.
    Chufan, Eduardo E.
    Fetsch, Patricia A.
    Shukla, Suneet
    Gill, Deborah R.
    Hyde, Stephen C.
    Xia, Di
    Ambudkar, Suresh V.
    Gottesman, Michael M.
    BIOCHEMISTRY, 2016, 55 (07) : 1010 - 1023
  • [26] Thiorhodamines containing amide and thioamide functionality as inhibitors of the ATP-binding cassette drug transporter P-glycoprotein (ABCB1)
    Orchard, Alexandra
    Schamerhorn, Gregory A.
    Calitree, Brandon D.
    Sawada, Geri A.
    Loo, Tip W.
    Bartlett, M. Claire
    Clarke, David M.
    Detty, Michael R.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (14) : 4290 - 4302
  • [27] DIRECT DEMONSTRATION OF HIGH-AFFINITY INTERACTIONS OF IMMUNOSUPPRESSANT DRUGS WITH THE DRUG-BINDING SITE OF THE HUMAN P-GLYCOPROTEIN
    RAO, US
    SCARBOROUGH, GA
    MOLECULAR PHARMACOLOGY, 1994, 45 (04) : 773 - 776
  • [28] Inhibition of Multidrug Resistance-Linked P-Glycoprotein (ABCB1) Function by 5′-Fluorosulfonylbenzoyl 5′-Adenosine: Evidence for an ATP Analogue That Interacts with Both Drug-Substrate-and Nucleotide-Binding Sites
    Ohnuma, Shinobu
    Chufan, Eduardo
    Nandigama, Krishnamachary
    Jenkins, Lisa M. Miller
    Durell, Stewart R.
    Appella, Ettore
    Sauna, Zuben E.
    Ambudkar, Suresh V.
    BIOCHEMISTRY, 2011, 50 (18) : 3724 - 3735
  • [29] Long-range communication between transmembrane- and nucleotide-binding domains does not depend on drug binding to mutant P-glycoprotein
    Bonito, Catia A.
    Ferreira, Ricardo J.
    Ferreira, Maria-Jose U.
    Gillet, Jean-Pierre
    Cordeiro, M. Natalia D. S.
    dos Santos, Daniel J. V. A.
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (23): : 14428 - 14437
  • [30] Human ABCB1 with an ABCB11-like degenerate nucleotide binding site maintains transport activity by avoiding nucleotide occlusion
    Goda, Katalin
    Donmez-Cakil, Yaprak
    Tarapcsak, Szabolcs
    Szaloki, Gabor
    Szollosi, Daniel
    Parveen, Zahida
    Turk, Dora
    Szakacs, Gergely
    Chiba, Peter
    Stockner, Thomas
    PLOS GENETICS, 2020, 16 (10):